Literature DB >> 28818983

Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies.

Lisa Bodei1, Valentina Ambrosini2, Ken Herrmann3,4, Irvin Modlin5.   

Abstract

68Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor-expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history; the histopathology and biomarker information; and the grade, stage, and prior imaging results. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false-positive results. This article provides a guide to the performance and interpretation of 68Ga-DOTATATE PET/CT and describes its role in the diagnostic algorithm of neuroendocrine neoplasms and its overall utility in their management.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  68Ga-DOTATATE; biodistribution; endocrine; neuroendocrine; oncology; peptides

Mesh:

Substances:

Year:  2017        PMID: 28818983     DOI: 10.2967/jnumed.116.186361

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  24 in total

1.  Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution.

Authors:  Rudolf A Werner; Heribert Hänscheid; Jeffrey P Leal; Mehrbod S Javadi; Takahiro Higuchi; Martin A Lodge; Andreas K Buck; Martin G Pomper; Constantin Lapa; Steven P Rowe
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

Review 2.  Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.

Authors:  Gary A Ulaner; C Ola Landgren
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

Review 3.  Functional imaging in ectopic Cushing syndrome.

Authors:  Seda Grigoryan; Anca M Avram; Adina F Turcu
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-06       Impact factor: 3.243

Review 4.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

5.  Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.

Authors:  Gary A Ulaner; Lisa Bodei
Journal:  Clin Nucl Med       Date:  2019-04       Impact factor: 7.794

Review 6.  What scans we will read: imaging instrumentation trends in clinical oncology.

Authors:  Thomas Beyer; Luc Bidaut; John Dickson; Marc Kachelriess; Fabian Kiessling; Rainer Leitgeb; Jingfei Ma; Lalith Kumar Shiyam Sundar; Benjamin Theek; Osama Mawlawi
Journal:  Cancer Imaging       Date:  2020-06-09       Impact factor: 3.909

7.  Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT.

Authors:  Divya Yadav; Sanjana Ballal; Madhav Prasad Yadav; Madhavi Tripathi; Frank Roesch; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-22       Impact factor: 9.236

8.  Enchondroma of Tibia as Potential False-positive Finding on 68Ga-DOTATOC PET/CT Scan.

Authors:  Sonia Mahajan; Lisa Bodei; Sandra Huicochea Castellanos; Ravinder K Grewal
Journal:  Clin Nucl Med       Date:  2019-01       Impact factor: 7.794

Review 9.  [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].

Authors:  Rudolf A Werner; Frank M Bengel; Thorsten Derlin
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

10.  Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.

Authors:  Stefano Partelli; Valentina Andreasi; Francesca Muffatti; Marco Schiavo Lena; Massimo Falconi
Journal:  Ann Surg Oncol       Date:  2020-04-06       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.